Melissa Larson

Ms. Melissa Larson

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2014 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
DKDevin C Koestler
Devin C Koestler
PCPrabhakar Chalise
Prabhakar Chalise
MCMine S Cicek
Mine S Cicek
JCJulie M Cunningham
Julie M Cunningham
SASebastian Armasu
Sebastian Armasu
EGEllen L Goode
Ellen L Goode
Both genetic and epigenetic factors influence the development and progression of epithelial ovarian cancer (EOC). However, there is an incomplete understanding of the interrelationship between these factors and the extent to which they interact to impact disease risk. In the present study, we aimed to gain insight into this relationship by identifying DNA methylation marks that are candidate mediators of ovarian cancer genetic risk.

28 April 2014 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
BFBrooke Fridley
Brooke Fridley
SASebastian Armasu
Sebastian Armasu
MCMine S Cicek
Mine S Cicek
MLMelissa Larson
Melissa Larson
CWChen Wang
Chen Wang
EGEllen L Goode
Ellen L Goode
Genome-wide interrogation of DNA methylation (DNAm) in blood-derived leukocytes has become feasible with the advent of CpG genotyping arrays. In epithelial ovarian cancer (EOC), one report found substantial DNAm differences between cases and controls; however, many of these disease-associated CpGs were attributed to differences in white blood cell type distributions.

13 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AOAnn L. Oberg
Ann L. Oberg
EHEthan P. Heinzen
Ethan P. Heinzen
XHXiaonan Hou
Xiaonan Hou
MHMariam M. Al Hilli
Mariam M. Al Hilli
RHRachel M. Hurley
Rachel M. Hurley
JWJohn Weroha
John Weroha
Repeated measures studies are frequently performed in patient-derived xenograft (PDX) models to evaluate drug activity or compare effectiveness of cancer treatment regimens. Linear mixed effects regression models were used to perform statistical modeling of tumor growth data. Biologically plausible structures for the covariation between repeated tumor burden measurements are explained. Graphical, tabular, and information criteria tools useful for choosing the mean model functional form and covariation structure are demonstrated in a Case Study of five PDX models comparing cancer treatments. Power calculations were performed via simulation. Linear mixed effects regression models applied to the natural log scale were shown to describe the observed data well. A straight growth function fit well for two PDX models. Three PDX models required quadratic or cubic polynomial (time squared or cubed) terms to describe delayed tumor regression or initial tumor growth followed by regression. Spatial(power), spatial(power) + RE, and RE covariance structures were found to be reasonable. Statistical power is shown as a function of sample size for different levels of variation. Linear mixed effects regression models provide a unified and flexible framework for analysis of PDX repeated measures data, use all available data, and allow estimation of tumor doubling time.

5 December 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
NMNicholas Mackrides
Nicholas Mackrides
JCJennifer Chapman
Jennifer Chapman
MLMelissa Larson
Melissa Larson
JRJuan C. Ramos
Juan C. Ramos
NTNgoc Toomey
Ngoc Toomey
FVFrancisco Vega
Francisco Vega

7 February 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
SYSamuel Yamshon
Samuel Yamshon
JKJean L. Koff
Jean L. Koff
MLMelissa Larson
Melissa Larson
BKBrad S. Kahl
Brad S. Kahl
CCCarla Casulo
Carla Casulo
LNLoretta J. Nastoupil
Loretta J. Nastoupil

1 May 2016 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JUJoseph L. Usset
Joseph L. Usset
RRRama Raghavan
Rama Raghavan
JTJonathan P. Tyrer
Jonathan P. Tyrer
VMValerie McGuire
Valerie McGuire
WSWeiva Sieh
Weiva Sieh
BFBrooke Fridley
Brooke Fridley
Background: Many epithelial ovarian cancer (EOC) risk factors relate to hormone exposure and elevated estrogen levels are associated with obesity in postmenopausal women. Therefore, we hypothesized that gene–environment interactions related to hormone-related risk factors could differ between obese and non-obese women. Methods: We considered interactions between 11,441 SNPs within 80 candidate genes related to hormone biosynthesis and metabolism and insulin-like growth factors with six hormone-related factors (oral contraceptive use, parity, endometriosis, tubal ligation, hormone replacement therapy, and estrogen use) and assessed whether these interactions differed between obese and non-obese women. Interactions were assessed using logistic regression models and data from 14 case–control studies (6,247 cases; 10,379 controls). Histotype-specific analyses were also completed. Results: SNPs in the following candidate genes showed notable interaction: IGF1R (rs41497346, estrogen plus progesterone hormone therapy, histology = all, P = 4.9 × 10−6) and ESR1 (rs12661437, endometriosis, histology = all, P = 1.5 × 10−5). The most notable obesity–gene–hormone risk factor interaction was within INSR (rs113759408, parity, histology = endometrioid, P = 8.8 × 10−6). Conclusions: We have demonstrated the feasibility of assessing multifactor interactions in large genetic epidemiology studies. Follow-up studies are necessary to assess the robustness of our findings for ESR1, CYP11A1, IGF1R, CYP11B1, INSR, and IGFBP2. Future work is needed to develop powerful statistical methods able to detect these complex interactions. Impact: Assessment of multifactor interaction is feasible, and, here, suggests that the relationship between genetic variants within candidate genes and hormone-related risk factors may vary EOC susceptibility. Cancer Epidemiol Biomarkers Prev; 25(5); 780–90. ©2016 AACR.